Trials / Completed
CompletedNCT01220141
Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
Prospective Observational Study on NovoSeven® Room Temperature Stable (VII25) in Patients With Haemophilia A or B
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 51 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Europe and Asia. The aim of this observational study is to monitor antibody formation towards the room temperature stable formulation of NovoSeven® (activated recombinant human factor VII).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | activated recombinant human factor VII | Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country. |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2010-10-13
- Last updated
- 2015-04-16
Locations
14 sites across 14 countries: Argentina, Austria, Belgium, France, Germany, Hungary, Iran, Ireland, Italy, Poland, Portugal, Slovakia, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT01220141. Inclusion in this directory is not an endorsement.